Compare · DXCM vs SGHT
DXCM vs SGHT
Side-by-side comparison of DexCom Inc. (DXCM) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.08B, about 51.6x SGHT ($601.9M).
- DXCM has been more active in the news (14 items in the past 4 weeks vs 6 for SGHT).
- DXCM has more recent analyst coverage (25 ratings vs 21 for SGHT).
- Company
- DexCom Inc.
- Sight Sciences Inc.
- Price
- -
- -
- Market cap
- $31.08B
- $601.9M
- 1M return
- -5.08%
- -
- 1Y return
- +43.50%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 14
- 6
- Recent ratings
- 25
- 21
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 96,734 units (SEC Form 4) to cover withholding tax
- EVP, COO & CFO Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.99% to 145,377 units (SEC Form 4) (for tax liability)
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 119,462 units (SEC Form 4) to satisfy withholding obligation
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 417,457 units (SEC Form 4) to satisfy withholding tax
- Dexcom Announces Upcoming Conference Presentation
- SEC Form SCHEDULE 13G filed by DexCom Inc.
- Director Ashley Euan A. gifted 2,389 shares (SEC Form 4)
- Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
- SEC Form 10-Q filed by DexCom Inc.
- SEC Form 8-K filed by DexCom Inc.
Latest SGHT
- Sight Sciences to Present at Two Upcoming Investor Conferences
- Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids
- SEC Form 10-Q filed by Sight Sciences Inc.
- Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance
- Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- H.C. Wainwright initiated coverage on Sight Sciences with a new price target
- EVP, Operations & R&D Taylor Brenton sold $26,453 worth of shares (2,988 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Bauerlein Alison sold $223,627 worth of shares (25,260 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Rodberg James sold $63,812 worth of shares (7,208 units at $8.85) as part of a pre-agreed trading plan (SEC Form 4)